Prognosis
Lilly Seeks Emergency Authorization for Covid Antibody Drug
- Company says 100,000 doses could be available this month
- Antibody may prevent symptomatic Covid cases from worsening
This article is for subscribers only.
Eli Lilly & Co. asked U.S. drug regulators to authorize emergency use of its experimental Covid-19 antibody therapy after data showed the treatment reduced hospitalizations.
The Indianapolis-based pharmaceutical giant has approached the U.S. Food and Drug Administration for authorization of the treatment it’s developing with Canadian biotech AbCellera Biologics Inc., according to a statement Wednesday. It would allow high-risk patients recently diagnosed with mild-to-moderate Covid-19 to receive the therapy.